RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
We endorse the new 2018 Expert Consensus Pathway from ACCinTouch, which addresses the changing paradigm in how cardiovascular specialists should approach care of patients with type 2 #diabetes. Read more. https://t.co/2RpQgAtsEx
RT @AmDiabetesAssn: We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiov…
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
We endorse the new 2018 Expert Consensus Pathway from @ACCinTouch, which addresses the changing paradigm in how cardiovascular specialists should approach care of patients with type 2 #diabetes. Read more.
RT @mbotana: Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease | JACC: Journal of the American College of Cardiology https://t.co/BixYtLYnrT
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease | JACC: Journal of the American College of Cardiology https://t.co/nrSiYAiLSY
RT @ZainabASamad: 422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc https://t.co/DgYHRhNW0r
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
422 million #diabetics #worldwide - we need all hands on deck. @yaleHFdoc
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
(JACC) Consenso de expertos de ACC 2018 sobre nuevas terapias para la reducción del riesgo cardiovascular en pacientes con diabetes tipo 2 y enfermedad cardiovascular aterosclerótica. https://t.co/Itlil48fNR. via @rincondesisifo #cardiovascular
Id preparando el ppt. Nuevas Terapias para Reducción de riesgo CV en Diabetes 2 de la AHA (con el respaldo de la ADA). Acceso libre. Ahora que, para sacarlo en estas fechas, digo yo que podrían haber esperado a tener los datos del DECLARE ¿no? https://t.co
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
A estudiar el consenso 2018 en el manejo de la Diabetes tipo II y enfermedad Arterioesclerosa. https://t.co/s8qh01xa0i https://t.co/LabGRqGBjR
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @SantasEnrique: DM 2 con enf CV establecida ➡️ control global FRCV (STENO-2) + iSGLT2/GLP-1; preferencia para empaglifozina y liraglutid…
RT @Office_j: 【雑記】ACCから、アテローム性CV疾患合併2型糖尿病に対する治療指針コンセンサス。2型DM例診療におけるCV専門医の重要性を強調。血統低下薬選択ではCVベネフィットも考慮——など。 JACC https://t.co/itHCoMtWzr ACC…
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @rincondesisifo: (JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
(JACC) Consenso del ACC sobre los nuevos ttos para ↓riesgo CV en pac con DM2 en prevención 2ª https://t.co/qzhA3sqwHx
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @SantasEnrique: DM 2 con enf CV establecida ➡️ control global FRCV (STENO-2) + iSGLT2/GLP-1; preferencia para empaglifozina y liraglutid…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
DM 2 con enf CV establecida ➡️ control global FRCV (STENO-2) + iSGLT2/GLP-1; preferencia para empaglifozina y liraglutide https://t.co/oPsFs6xW49 @Raquelsegpor @JACCJournals https://t.co/2zO2T1tYVc
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @SJGreene_md: A really great resource that will hopefully improve cardiologist comfort with discussing these therapies with patients and…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
【雑記】ACCから、アテローム性CV疾患合併2型糖尿病に対する治療指針コンセンサス。2型DM例診療におけるCV専門医の重要性を強調。血統低下薬選択ではCVベネフィットも考慮——など。 JACC https://t.co/itHCoMtWzr ACC解説 https://t.co/B3Soxjy90G https://t.co/TyDjiztvoo
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @SJGreene_md: A really great resource that will hopefully improve cardiologist comfort with discussing these therapies with patients and…
This is awesome. Much needed. Giving a PCP inservice on GLP1s this week and this could not have been more timely. I especially like Table 11!
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @mvaduganathan: 2018 @ACCinTouch Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients With #T2DM & #AS…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @Dr_Manito: Nuevo consenso ACC-2018 en toma de decisiones con las nuevas terapias para reducir riesgo CV en pacientes con diabetes melli…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @DanielJDrucker: 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @SJGreene_md: A really great resource that will hopefully improve cardiologist comfort with discussing these therapies with patients and…
RT @paomorejon: 📌 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 D…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…
RT @JJheart_doc: An important Expert Consensus document from the ACC. Cardiologists must learn novel diabetes therapies for optimal manage…